Clinical trials: Vomit
Nausea and Vomiting of Pregnancy
The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy
The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo.
- Trial name
- NCT00614445
- Testing
- doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
- Where
- 7 sites in United States
- Volunteers
- 280 people
- Sponsor
- Duchesnay Inc.
Nausea and Vomiting, Postoperative
Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients
Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting
- Trial name
- NCT05546359
- Testing
- Amisulpride Injection, Dexamethasone
- Where
- 14 sites in United States, Canada and 2 more
- Volunteers
- 453 people
- Sponsor
- Acacia Pharma Ltd
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of…
- Trial name
- NCT00104403
- Testing
- GW679769, Dexamethasone, Ondansetron Hydrochloride
- Where
- 113 sites in United States, Argentina and 22 more
- Volunteers
- 722 people
- Sponsor
- GlaxoSmithKline
Chemotherapy Induced Nausea and Vomiting
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring…
- Trial name
- NCT00642512
- Testing
- dronabinol, ondansetron, dronabinol/ondansetron
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- Solvay Pharmaceuticals
Chemotherapy Induced Nausea and Vomiting
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.
- Trial name
- C-PHONE (NCT00211601)
- Testing
- Disease Management Assessment
- Volunteers
- 1,500 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
- Trial name
- CINV (NCT04817189)
- Testing
- NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
- Where
- 19 sites in China, Czechia and 5 more
- Volunteers
- 414 people
- Sponsor
- Helsinn Healthcare SA
Nausea, Vomiting
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to determine whether palonosetron is tolerate and effective in preventing chemotherapy-induced nausea and vomiting in oriental population.
- Conditions
- Nausea, Vomiting, Chemotherapy
- Trial name
- NCT00503386
- Testing
- Palonosetron, Granisetron
- Where
- 6 sites in China
- Volunteers
- 144 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Neoplasms, Nausea
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron 0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and vomiting induced by moderately emetogenic…
- Conditions
- Neoplasms, Nausea, Vomiting
- Trial name
- NCT00687011
- Testing
- Palonosetron and Dexamethasone
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic…
- Trial name
- NCT04054193
- Testing
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Where
- 26 sites in United States, Greece and 7 more
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting
A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
- Trial name
- NCT00990821
- Testing
- 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Nausea and Vomiting
Phase II Dose-ranging Study of APD421 in PONV
To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV.
- Trial name
- NCT01510704
- Testing
- APD421
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 215 people
- Sponsor
- Acacia Pharma Ltd
Nausea and Vomitting
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: To check for side effects from treatment with TAK-951.
- Trial name
- NCT06768658
- Testing
- TAK-951
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Takeda
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Postoperative
Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
PROMPT (PONV Rescue Outcomes after AMisulPride Treatment) is an observational Phase IV study designed to evaluate real-world evidence in relation to the care continuum of Post Operative Nausea and Vomiting (PONV), as well as the…
- Trial name
- PROMPT (NCT04954365)
- Testing
- Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC), Amisulpride
- Sponsor
- Acacia Pharma Ltd
Gastroenteritis
Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis
A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.
- Trial name
- NCT05876585
- Testing
- Ondansetron 8 mg ampoule, Metoclopramide 10 mg ampoule
- Volunteers
- 126 people
- Sponsor
- Genuine Research Center, Egypt
Nausea and Vomiting, Chemotherapy-Induced
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of…
- Trial name
- NCT00601172
- Testing
- Casopitant, Dexamethasone, Ondansetron
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 710 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Prevention of Unmitigated Chemotherapy-induced Emesis
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life.
- Trial name
- PUCE (NCT03996863)
- Testing
- Otoband
- Where
- United States
- Sponsor
- Otolith Labs
Chemotherapy-induced Nausea and Vomiting, Prophylaxis
Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of palonosetron after intravenous administration of palonosetron in healthy volunteers under fasting conditions.
- Trial name
- NCT04585412
- Testing
- Palonosetron
- Where
- Taiwan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Postoperative Pain
An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours
To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two…
- Trial name
- NCT01082471
- Testing
- Morphine 6-glucuronide, Morphine
- Where
- 7 sites in Czechia, France and 4 more
- Volunteers
- 517 people
- Sponsor
- Paion UK Ltd.